<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62223">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096536</url>
  </required_header>
  <id_info>
    <org_study_id>S56376</org_study_id>
    <nct_id>NCT02096536</nct_id>
  </id_info>
  <brief_title>Exploring Vancomycin Disposition in Neonates</brief_title>
  <official_title>Exploring Vancomycin Disposition in Neonates: Paired Analysis of Vancomycin Concentrations Using Immunoassay and Liquid-chromatography-tandem Mass Spectrometry. Determination of Vancomycin Protein Binding and Its Covariates in Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin is already used for decades in neonates. However, there are remaining questions
      concerning vancomycin disposition in this population. The purpose of this study is first of
      all to perform a paired analysis of serum vancomycin concentrations using an immunoassay
      versus a reference liquid chromatography-tandem mass spectrometry method. Secondly, we aim
      to determine vancomycin protein binding and its covariates in neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploration of vancomycin disposition in neonates:

      Objective 1: Paired analysis of (total) serum vancomycin concentrations in neonates using
      the currently available immunoassay (Cobas c702) versus a reference liquid
      chromatography-tandem mass spectrometry method (LC-MS/MS).

      Objective 2: The determination of vancomycin protein binding and its covariates in neonates.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Differences in vancomycin exposure</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Paired vancomycin concentrations in 60 neonates using an immunoassay versus LC/MS-MS method.
Total versus unbound vancomycin concentrations in 60 neonates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of freezing and thawing on vancomycin measurement</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparisson of the same analytical technique (immunoassay) in fresh (routine clinical care) versus stored samples .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Neonatal Infection</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All included patients receive vancomycin for medical reasons. Decision for start of therapy is made by the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>NA</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates, admitted to the Neonatal Intensive Care Unit to whom vancomycin is
             administered for medical reasons, can be included in the study after informed consent
             of the parents.

        Exclusion Criteria:

          -  No vancomycin therapy

          -  No signed informed consent available
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Smits, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Smits, MD</last_name>
    <phone>003216341564</phone>
    <email>anne.smits@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karel Allegaert, MD, PhD</last_name>
    <phone>003216343210</phone>
    <email>karel.allegaert@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Smits, MD</last_name>
      <phone>003216341564</phone>
      <email>anne.smits@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Karel Allegaert, MD,PhD</last_name>
      <phone>003216343210</phone>
      <email>karel.allegaert@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Karel Allegaert, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Smits, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonate</keyword>
  <keyword>Vancomycin</keyword>
  <keyword>LC/MS-MS</keyword>
  <keyword>protein binding</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
